| Literature DB >> 34178060 |
Augusto Cézar Lacerda Brasileiro1, Dinaldo Cavalcanti de Oliveira2, Pollianne Barbosa da Silva1, João Kairo Soares de Lima Rocha1.
Abstract
BACKGROUND: The human skin is an extremely sophisticated and evolved organ that covers the whole body. External agents or the patient's own diseases can cause skin injuries that can challenge healthcare professionals and impose high social, economic and emotional costs.Entities:
Keywords: collagens; polymorphonuclear cells; topical nifedipine; vascular proliferation; wound
Year: 2020 PMID: 34178060 PMCID: PMC8202160 DOI: 10.1590/1677-5449.190092
Source DB: PubMed Journal: J Vasc Bras ISSN: 1677-5449
Figure 1Skin removal down to the dorsal muscular fascia and corresponding letters.
Figure 2Macroscopic evaluation at the time of wound creation (A) and on day 21, with a centimeter rule (B).
Proportion of marked PMN, vascular proliferation, and collagen levels in wounds treated with nifedipine 1% versus placebo.
| Data collections | Polymorphonuclear (Marked) | Vascular Proliferation (Marked) | Collagen (Marked) | |||
|---|---|---|---|---|---|---|
| Control | Nifedipine 1% | Control | Nifedipine 1% | Control | Nifedipine 1% | |
| N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |
| Day 1 | 1 (25%) | 3 (75%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Day 3 | 0 (0%) | 4 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Day 7 | 3 (75%) | 3 (75%) | 2 (50%) | 3 (75%) | 0 (0%) | 0 (0%) |
| Day 14 | 4 (100%) | 4 (100%) | 3 (75%) | 4 (100%) | 1 (25%) | 1 (25%) |
| Day 21 | 1 (25%) | 0 (0%) | 2 (50%) | 3 (75%) | 2 (50%) | 2 (50%) |
| Day 28 | 1 (25%) | 3 (75%) | 1 (25%) | 1 (25%) | 4 (100%) | 4 (100%) |
| Nifedipine 1% | OR = 3.5 (CI95%: 1.04 – 11.7) | OR = 1.76 (CI95%: 0.52 – 5.93) | OR = 1.0 (CI95%: 0.12 – 8.62) | |||
| p-value | 0.044 | 0.361 | 1.000 | |||
N – Number; OR – Odds Ratio; CI – Confidence Interval.
Figure 3Polymorphonuclear levels. Marked (A), Moderate (B), and Mild (C). See arrows. Hematoxylin-eosin (40 x magnification).
Proportion of marked PMN, vascular proliferation, and collagen levels in wounds treated with nifedipine 10% versus placebo.
|
|
|
|
| |||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
| Day 1 | 0 (0%) | 4 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Day 3 | 0 (0%) | 4 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Day 7 | 1 (25%) | 2 (50%) | 4(100%) | 3 (75%) | 0 (0%) | 0 (0%) |
| Day 14 | 0 (0%) | 2 (50%) | 4(100%) | 4 (100%) | 0 (0%) | 0 (0%) |
| Day 21 | 3 (75%) | 3 (75%) | 3 (75%) | 4 (100%) | 3 (75%) | 0 (0%) |
| Day 28 | 1 (25%) | 3 (75%) | 0 (0%) | 3 (75%) | 4 (100%) | 2 (50%) |
| Nifedipine 10% | OR = 11.8 (CI95%: 2.99 – 46.2) | OR = 1.78 (CI95%: 0.52 – 6.12) | OR = 0.02 (CI95%: 0.04 – 10.2) | |||
| p-value | <0.001 | 0.355 | 0.986 | |||
N – Number; OR – Odds Ratio; CI – Confidence Interval.
Proportion of marked PMN, vascular proliferation, and collagen levels in wounds treated with nifedipine 20% versus placebo.
|
|
|
|
| |||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
| Day 1 | 0 (0%) | 4 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Day 3 | 1 (25%) | 4 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Day 7 | 1 (25%) | 2 (50%) | 3 (75%) | 4 (100%) | 2 (50%) | 0 (0%) |
| Day 14 | 2 (50%) | 3 (75%) | 2 (50%) | 3 (75%) | 1 (25%) | 0 (0%) |
| Day 21 | 0 (0%) | 4 (100%) | 0 (0%) | 3 (75%) | 4 (100%) | 1 (25%) |
| Day 28 | 0 (0%) | 2 (50%) | 0 (0%) | 3 (75%) | 4 (100%) | 1 (25%) |
| Nifedipine 20% | OR = 22.1 (CI95%: 4.67–104.0) | OR = 4.84 (CI95%: 1.30–18.0) | OR = 0.02 (CI95%: 0.00- 0.28) | |||
| p-value | <0.001 | 0.019 | 0.005 | |||
N – Number; OR – Odds Ratio; CI – Confidence Interval.
Figure 4Vascular Proliferation levels. Marked (A), Moderate (B) and Mild (C). See arrows. Hematoxylin-eosin (40 x magnification).
Figure 5Collagen levels. Marked (A), Moderate (B) and Mild (C). See arrows. Hematoxylin-eosin (40 x magnification).
Figure 6Analysis of the 12 NFD-treated wounds versus the 12 placebo-treated wounds in the three animals. A = polymorphonuclear cells (PMNs); B = vascular proliferation; C = collagen.